Goldman Sachs’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Goldman Sachs’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27,120	Closed	-$80K	–	6782
2021 Q3	$80K	Sell	27,120 -29,193	-52%	-$98.1K	﹤0.01%	5951
2021 Q2	$169K	Buy	56,313 +6,455	+13%	+$19.8K	﹤0.01%	5801
2021 Q1	$162K	Buy	49,858 +7,758	+18%	+$31.9K	﹤0.01%	5712
2020 Q4	$174K	Sell	42,100 -7,760	-16%	-$44.7K	﹤0.01%	5135
2020 Q3	$270K	Sell	49,860 -7,550	-13%	-$43.5K	﹤0.01%	4787
2020 Q2	$387K	Buy	57,410 +32,985	+135%	+$161K	﹤0.01%	4508
2020 Q1	$78K	Buy	24,425 +2,679	+12%	+$14.3K	﹤0.01%	4984
2019 Q4	$152K	Buy	+21,746	New	+$116K	﹤0.01%	4971
2019 Q3	–	Sell	-15,691	Closed	-$60K	–	5439
2019 Q2	$60K	Buy	+15,691	New	+$52.2K	﹤0.01%	5005

Other funds holding RVLP

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's RVLP Position: Q4 2021 in Review

Goldman Sachs sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2021, closing a stake of 27,120 shares — an estimated $80K sold.

Goldman Sachs first reported a position in RVLP in Q2 2019 and held it in 9 quarters. The position peaked at $387K in Q2 2020. 31 funds tracked by Wall St. Rank hold RVLP as of Q4 2021.

Goldman Sachs reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 27,120 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2021, an estimated $80K.
Goldman Sachs first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2019 and held it in 9 quarters.
Goldman Sachs's RVL Pharmaceuticals plc Ordinary Shares position peaked at $387K in Q2 2020.
31 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.